WO2002046192A3 - Thioether substituted imidazoquinolines - Google Patents

Thioether substituted imidazoquinolines Download PDF

Info

Publication number
WO2002046192A3
WO2002046192A3 PCT/US2001/046697 US0146697W WO0246192A3 WO 2002046192 A3 WO2002046192 A3 WO 2002046192A3 US 0146697 W US0146697 W US 0146697W WO 0246192 A3 WO0246192 A3 WO 0246192A3
Authority
WO
WIPO (PCT)
Prior art keywords
thioether substituted
useful
substituted imidazoquinolines
compounds
imidazoquinolines
Prior art date
Application number
PCT/US2001/046697
Other languages
French (fr)
Other versions
WO2002046192A2 (en
Inventor
Joseph F Dellaria
Bryon A Merrill
Matthew R Radmer
Original Assignee
3M Innovative Properties Co
Joseph F Dellaria
Bryon A Merrill
Matthew R Radmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL366330A priority Critical patent/PL207340B1/en
Priority to DE60111076T priority patent/DE60111076T2/en
Application filed by 3M Innovative Properties Co, Joseph F Dellaria, Bryon A Merrill, Matthew R Radmer filed Critical 3M Innovative Properties Co
Priority to EEP200300275A priority patent/EE200300275A/en
Priority to AT01987297T priority patent/ATE296301T1/en
Priority to NZ526087A priority patent/NZ526087A/en
Priority to DK01987297T priority patent/DK1341791T3/en
Priority to IL15590401A priority patent/IL155904A0/en
Priority to MXPA03004975A priority patent/MXPA03004975A/en
Priority to EP01987297A priority patent/EP1341791B1/en
Priority to HU0400710A priority patent/HUP0400710A2/en
Priority to SI200130382T priority patent/SI1341791T1/en
Priority to KR10-2003-7007534A priority patent/KR20030070049A/en
Priority to JP2002547929A priority patent/JP2004515500A/en
Priority to AU2002239530A priority patent/AU2002239530B2/en
Priority to SK710-2003A priority patent/SK287264B6/en
Priority to CA2436846A priority patent/CA2436846C/en
Priority to BR0116026-5A priority patent/BR0116026A/en
Priority to AU3953002A priority patent/AU3953002A/en
Publication of WO2002046192A2 publication Critical patent/WO2002046192A2/en
Publication of WO2002046192A3 publication Critical patent/WO2002046192A3/en
Priority to NO20032595A priority patent/NO20032595D0/en
Priority to CY20051101024T priority patent/CY1105586T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)

Abstract

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
PCT/US2001/046697 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines WO2002046192A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CA2436846A CA2436846C (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
HU0400710A HUP0400710A2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines, their use and pharmaceutical compositions containing them
EEP200300275A EE200300275A (en) 2000-12-08 2001-12-06 Thioether-substituted imidazoquinolines
AT01987297T ATE296301T1 (en) 2000-12-08 2001-12-06 THIOETHER SUBSTITUTED IMIDAZOCINOLINES
NZ526087A NZ526087A (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
DK01987297T DK1341791T3 (en) 2000-12-08 2001-12-06 Thioether-substituted imidazoquinolines
IL15590401A IL155904A0 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
MXPA03004975A MXPA03004975A (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines.
KR10-2003-7007534A KR20030070049A (en) 2000-12-08 2001-12-06 Thioether Substituted Imidazoquinolines
PL366330A PL207340B1 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
SI200130382T SI1341791T1 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
EP01987297A EP1341791B1 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
JP2002547929A JP2004515500A (en) 2000-12-08 2001-12-06 Thioether-substituted imidazoquinoline
AU2002239530A AU2002239530B2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
SK710-2003A SK287264B6 (en) 2000-12-08 2001-12-06 Imidazoquinoline and tetrahydroimidazoquinoline derivatives, pharmaceutical compositions containing thereof and use thereof
DE60111076T DE60111076T2 (en) 2000-12-08 2001-12-06 THIOETHERSUBSTITUTED IMIDAZOCHINOLINE
BR0116026-5A BR0116026A (en) 2000-12-08 2001-12-06 Thioether-Replaced Imidazoquinolines
AU3953002A AU3953002A (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines
NO20032595A NO20032595D0 (en) 2000-12-08 2003-06-06 Tioether-substituted imidazoquinolines
CY20051101024T CY1105586T1 (en) 2000-12-08 2005-08-24 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25421800P 2000-12-08 2000-12-08
US60/254,218 2000-12-08

Publications (2)

Publication Number Publication Date
WO2002046192A2 WO2002046192A2 (en) 2002-06-13
WO2002046192A3 true WO2002046192A3 (en) 2003-02-13

Family

ID=22963391

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2001/046359 WO2002046188A2 (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
PCT/US2001/046696 WO2002046191A2 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
PCT/US2001/046582 WO2002046190A2 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines
PCT/US2001/046581 WO2002046189A2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
PCT/US2001/046704 WO2002046193A2 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines
PCT/US2001/046697 WO2002046192A2 (en) 2000-12-08 2001-12-06 Thioether substituted imidazoquinolines

Family Applications Before (5)

Application Number Title Priority Date Filing Date
PCT/US2001/046359 WO2002046188A2 (en) 2000-12-08 2001-12-06 Amido ether substituted imidazoquinolines
PCT/US2001/046696 WO2002046191A2 (en) 2000-12-08 2001-12-06 Urea substituted imidazoquinoline ethers
PCT/US2001/046582 WO2002046190A2 (en) 2000-12-08 2001-12-06 Sulfonamido ether substituted imidazoquinolines
PCT/US2001/046581 WO2002046189A2 (en) 2000-12-08 2001-12-06 Aryl ether substituted imidazoquinolines
PCT/US2001/046704 WO2002046193A2 (en) 2000-12-08 2001-12-06 Heterocyclic ether substituted imidazoquinolines

Country Status (32)

Country Link
US (8) US6670372B2 (en)
EP (6) EP1343784B1 (en)
JP (7) JP2004515501A (en)
KR (6) KR20040047733A (en)
CN (6) CN1247575C (en)
AR (6) AR035669A1 (en)
AT (3) ATE296301T1 (en)
AU (12) AU2002232482B2 (en)
BR (6) BR0116470A (en)
CA (6) CA2430844A1 (en)
CY (2) CY1105586T1 (en)
CZ (6) CZ20031562A3 (en)
DE (3) DE60126645T2 (en)
DK (3) DK1341791T3 (en)
EE (6) EE200300271A (en)
ES (3) ES2260323T3 (en)
HK (3) HK1064383A1 (en)
HR (6) HRP20030466A2 (en)
HU (6) HUP0400710A2 (en)
IL (6) IL155950A0 (en)
MX (6) MXPA03005012A (en)
NO (6) NO20032449D0 (en)
NZ (6) NZ526106A (en)
PL (7) PL392462A1 (en)
PT (2) PT1341790E (en)
RU (6) RU2315049C2 (en)
SI (1) SI1341790T1 (en)
SK (6) SK6842003A3 (en)
TW (3) TWI222972B (en)
UA (2) UA74852C2 (en)
WO (6) WO2002046188A2 (en)
ZA (6) ZA200305270B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
WO2004080430A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
IL147953A (en) 2002-02-01 2008-04-13 Meir Bialer Derivatives and pharmaceutical compositions of n-hydroxymethyl tetramethylcyclopropyl-
EP1478327B1 (en) * 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2003237386A1 (en) * 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
AU2003281340B2 (en) 2002-07-02 2009-04-09 Southern Research Institute Inhibitors of FtsZ and uses thereof
ATE488246T1 (en) 2002-08-15 2010-12-15 3M Innovative Properties Co IMMUNO-STIMULATORY COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
AU2004220534A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1H-imidazoquinolines
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006523212A (en) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
JP2006520245A (en) 2003-03-13 2006-09-07 スリーエム イノベイティブ プロパティズ カンパニー How to remove a tattoo
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2521682A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
JP2007501252A (en) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Formulation containing immune response modifier
AR045260A1 (en) * 2003-08-12 2005-10-19 3M Innovative Properties Co COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED
EP2939693A1 (en) * 2003-08-14 2015-11-04 3M Innovative Properties Company Lipid-modified immune response modifiers
ES2545826T3 (en) * 2003-08-14 2015-09-16 3M Innovative Properties Company Lipid Modified Immune Response Modifiers
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2005018574A2 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AR045529A1 (en) 2003-08-27 2005-11-02 3M Innovative Properties Co IMIDAZOQUINOLINAS REPLACED WITH ARILOXI OR ARILALQUILENOXI GROUPS
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
US20050054665A1 (en) * 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
JP2007505629A (en) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Selective regulation of TLR gene expression
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
SG149829A1 (en) 2003-10-03 2009-02-27 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CN1897948A (en) * 2003-10-03 2007-01-17 3M创新有限公司 Alkoxy substituted imidazoquinolines
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co Oxime substituted imidazo ring compounds
PL1687305T3 (en) * 2003-11-21 2008-12-31 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
AR046845A1 (en) * 2003-11-21 2005-12-28 Novartis Ag DERIVATIVES OF 1H-IMIDAZO [4,5-C] QUINOLINE FOR THE TREATMENT OF PROTEIN-KINASE DEPENDENT DISEASES
JP4891088B2 (en) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー Substituted imidazo ring systems and methods
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
CN1914203A (en) * 2003-12-04 2007-02-14 3M创新有限公司 Sulfone substituted imidazo ring ethers
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
JP2007517035A (en) * 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US20050158325A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
JP4991520B2 (en) * 2004-03-15 2012-08-01 スリーエム イノベイティブ プロパティズ カンパニー Immune response modulator formulation and method
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co Methods, compositions, and preparations for delivery of immune response modifiers
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006009832A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
AU2005282726B2 (en) * 2004-09-02 2011-06-02 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2006031878A2 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co Adjuvant for dna vaccines
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP1831226B1 (en) * 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
CA2594253C (en) 2004-12-30 2015-08-11 3M Innovative Properties Company Treatment for cutaneous metastases
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
ES2475728T3 (en) 2005-02-09 2014-07-11 3M Innovative Properties Company Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
CN101203529A (en) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ES2595363T3 (en) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis associated with meningitis proteins and nucleic acids / Escherichia coli
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
CA2598437A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
JP2008533148A (en) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー Treatment method for actinic keratosis
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP2009507856A (en) 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Amide and carbamate derivatives of N- {2- [4-amino-2- (ethoxymethyl) -1H-imidazo [4,5-c] quinolin-1-yl] -1,1-dimethylethyl} methanesulfonamide and Method
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PT2368572T (en) 2005-11-04 2020-06-16 Seqirus Uk Ltd Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1948173B1 (en) 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
EP2377551A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2619160T7 (en) 2006-01-27 2020-07-29 Seqirus Uk Ltd Flu vaccines containing hemagglutinin and matrix proteins
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
ES2536426T3 (en) 2006-03-23 2015-05-25 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
ES2388556T3 (en) * 2006-03-23 2012-10-16 Novartis Ag Immunopotentiating compounds
JP2009534303A (en) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Preserving influenza vaccines that are not refrigerated
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (en) 2006-06-09 2012-01-02 Novartis Ag Conformers of bacterial adhesins
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EA200900784A1 (en) 2006-12-06 2009-12-30 Новартис Аг VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
PL2185191T3 (en) 2007-06-27 2013-02-28 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008347400B2 (en) * 2008-01-15 2014-12-11 Meda Ab Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
NZ588191A (en) 2008-03-03 2012-06-29 Irm Llc Compounds and compositions as tlr activity modulators
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
CN102548577A (en) 2009-04-27 2012-07-04 诺华有限公司 Adjuvanted vaccines for protecting against influenza
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN105214080A (en) 2009-07-15 2016-01-06 诺华股份有限公司 RSV F protein compositions and its manufacture method
PL2464658T3 (en) 2009-07-16 2015-03-31 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
RS55819B1 (en) 2010-08-17 2017-08-31 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
EP2651937B8 (en) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
EP2667892B1 (en) 2011-01-26 2019-03-27 GlaxoSmithKline Biologicals SA Rsv immunization regimen
PT3275892T (en) 2011-05-13 2020-04-08 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
BR112013031039B1 (en) 2011-06-03 2020-04-28 3M Innovative Properties Co hydrazine compounds 1h-imidazoquinoline-4-amines, conjugates made from these compounds, composition and pharmaceutical composition comprising said compounds and conjugates, uses thereof and method of manufacturing the conjugate
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
LT2941233T (en) 2013-01-07 2020-10-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP3632458A1 (en) 2013-07-26 2020-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
EP3065741B1 (en) 2013-11-05 2021-09-22 3M Innovative Properties Company Sesame oil based injection formulations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
JP2017503803A (en) 2014-01-10 2017-02-02 シャンハイ バーディー バイオテック インコーポレイテッド Compounds and compositions for treating EGFR expressing tumors
KR20160132109A (en) 2014-03-26 2016-11-16 글락소스미스클라인 바이오로지칼즈 에스.에이. Mutant staphylococcal antigens
CN105233291A (en) 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
CN105440135A (en) 2014-09-01 2016-03-30 博笛生物科技有限公司 Anti-PD-L1 conjugate for treating tumors
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN105461767B (en) * 2014-08-07 2019-03-12 富力 A kind of chemical synthesis process of forsythin
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
RU2722149C1 (en) * 2015-09-14 2020-05-27 Пфайзер Инк. New derivatives of imidazo [4,5-c] quinolines and imidazo [4,5-c] [1,5] naphthyridines as lrrk2 inhibitors
JP2018531318A (en) * 2015-09-29 2018-10-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Polymer conjugate vaccine
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN115252792A (en) 2016-01-07 2022-11-01 博笛生物科技有限公司 anti-EGFR combinations for the treatment of tumors
CN110234401B (en) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 Methods and compositions for adaptive immunomodulation
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
JP7080501B2 (en) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
JP2021512953A (en) 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド Small molecule drug conjugate of gemcitabine monophosphate
SG11202007518RA (en) 2018-02-28 2020-09-29 Pfizer Il-15 variants and uses thereof
US11370788B2 (en) * 2018-02-28 2022-06-28 3M Innovative Properties Company Substituted imidazo[4,5-c]quinoline compounds with an N-1 branched group
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
KR102602329B1 (en) 2018-05-23 2023-11-16 화이자 인코포레이티드 Antibodies specific for CD3 and their uses
CA3101277A1 (en) * 2018-05-24 2019-11-28 3M Innovative Properties Company N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
US20210213010A1 (en) * 2018-07-24 2021-07-15 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
EP3887369A1 (en) * 2018-11-26 2021-10-06 3M Innovative Properties Company N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3921322A4 (en) * 2019-02-07 2022-07-20 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
KR20210136014A (en) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 Compositions, methods and uses thereof containing antibody-TLR agonist conjugates
CN114599360A (en) * 2019-10-29 2022-06-07 骏达贸易有限公司 4-amino-imidazoquinoline compounds and uses thereof
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN116323668A (en) 2020-07-17 2023-06-23 辉瑞公司 Therapeutic antibodies and uses thereof
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
WO1995002598A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2135210A (en) * 1937-03-13 1938-11-01 John R Farrar Golf ball
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3692907A (en) * 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3819190A (en) * 1972-10-02 1974-06-25 D Nepela Golf ball
US4284276A (en) * 1980-02-13 1981-08-18 Worst Joseph C Grooved golf ball
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5054153A (en) * 1989-12-01 1991-10-08 Silliman Paul D Golf club cleaner
WO1992006093A1 (en) * 1990-10-05 1992-04-16 Minnesota Mining And Manufacturing Company Process for the preparation of imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2692159B1 (en) * 1992-06-10 1996-10-11 Vartan Berberian BALL FOR BALL GAMES AND METHODS OF OBTAINING SUCH A BALL.
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
ATE195735T1 (en) 1993-07-15 2000-09-15 Minnesota Mining & Mfg IMIDAZO (4,5-C)PYRIDINE-4-AMINE
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09116911A (en) * 1995-10-20 1997-05-02 Canon Inc Image pickup system
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5759109A (en) * 1996-09-09 1998-06-02 Martini; Byron Rocco Simulated golf ball instructional device
EP0938315B9 (en) * 1996-10-25 2008-02-20 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
US6239965B1 (en) * 1998-05-22 2001-05-29 Matsushita Electric Industrial Co., Ltd. Electrolytic capacitor and method of producing the same
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CA2361936C (en) * 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664260B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
CA2430206A1 (en) 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
EP1401437A1 (en) 2001-06-15 2004-03-31 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
CA2458876A1 (en) 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US20030139364A1 (en) 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
WO2004080430A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
EP1450804B9 (en) 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1478327B1 (en) 2002-02-22 2015-04-29 Meda AB Method of reducing and treating uvb-induced immunosuppression
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AU2003237386A1 (en) 2002-06-07 2003-12-22 3M Innovative Properties Company Ether substituted imidazopyridines
ATE488246T1 (en) 2002-08-15 2010-12-15 3M Innovative Properties Co IMMUNO-STIMULATORY COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
JP2006503068A (en) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003301052A1 (en) * 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
AU2004218349A1 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
AU2004220534A1 (en) 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1H-imidazoquinolines
JP2006523212A (en) 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー Diagnosis method of skin lesion
JP2006520245A (en) 2003-03-13 2006-09-07 スリーエム イノベイティブ プロパティズ カンパニー How to remove a tattoo
JP2006523452A (en) 2003-03-25 2006-10-19 スリーエム イノベイティブ プロパティズ カンパニー Selective activation of cellular activity mediated through a common Toll-like receptor
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
CA2521682A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EA200600540A1 (en) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. INTRODUCTION OF TLR7 LIGANDS AND THEIR TREATMENTS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1995002598A1 (en) * 1993-07-15 1995-01-26 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9186400B2 (en) 2009-03-25 2015-11-17 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9504742B2 (en) 2009-03-25 2016-11-29 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Also Published As

Publication number Publication date
RU2308456C2 (en) 2007-10-20
BR0116464A (en) 2006-02-21
HUP0600600A2 (en) 2006-11-28
CZ303462B6 (en) 2012-09-26
RU2003116059A (en) 2005-02-10
HK1069166A1 (en) 2005-05-13
RU2315049C2 (en) 2008-01-20
AR035665A1 (en) 2004-06-23
NZ526105A (en) 2004-11-26
DE60117859D1 (en) 2006-05-04
CY1106569T1 (en) 2012-01-25
EE200300271A (en) 2003-10-15
CN1297554C (en) 2007-01-31
KR20030070049A (en) 2003-08-27
MXPA03005012A (en) 2003-09-05
NO20032452D0 (en) 2003-05-28
EE200300270A (en) 2003-10-15
NO20032451D0 (en) 2003-05-28
PT1341791E (en) 2005-09-30
HK1064383A1 (en) 2005-01-28
NO20032451L (en) 2003-07-16
AU2002230618B2 (en) 2006-11-02
ES2242782T3 (en) 2005-11-16
BR0116032A (en) 2006-02-21
NO20032452L (en) 2003-07-16
US6683088B2 (en) 2004-01-27
BR0116047A (en) 2003-09-30
US6953804B2 (en) 2005-10-11
EP1341791B1 (en) 2005-05-25
SK7102003A3 (en) 2003-10-07
IL156044A0 (en) 2003-12-23
US20050234088A1 (en) 2005-10-20
MXPA03004974A (en) 2003-09-05
CN1252070C (en) 2006-04-19
WO2002046192A2 (en) 2002-06-13
BR0116026A (en) 2004-12-21
EP1341790B1 (en) 2007-02-14
NO20032449L (en) 2003-05-28
DK1343784T3 (en) 2006-07-10
UA74852C2 (en) 2006-02-15
CN1487939A (en) 2004-04-07
CZ20031560A3 (en) 2004-05-12
US6670372B2 (en) 2003-12-30
CZ20031562A3 (en) 2004-03-17
CA2436846C (en) 2010-11-16
JP4437189B2 (en) 2010-03-24
US7132429B2 (en) 2006-11-07
WO2002046189A2 (en) 2002-06-13
IL156043A0 (en) 2003-12-23
CA2436980A1 (en) 2002-06-13
EP1341789A2 (en) 2003-09-10
BR0116052A (en) 2006-02-21
EP1341790A2 (en) 2003-09-10
CA2436846A1 (en) 2002-06-13
US20040077678A1 (en) 2004-04-22
AU3249702A (en) 2002-06-18
US6656938B2 (en) 2003-12-02
PL361948A1 (en) 2004-10-18
SK287732B6 (en) 2011-07-06
AR035667A1 (en) 2004-06-23
DE60111076T2 (en) 2006-05-04
PL365995A1 (en) 2005-01-24
AU3951602A (en) 2002-06-18
SI1341790T1 (en) 2007-06-30
RU2003116649A (en) 2005-02-10
WO2002046190A3 (en) 2003-07-17
US20050148619A1 (en) 2005-07-07
NO20032449D0 (en) 2003-05-28
IL155903A0 (en) 2003-12-23
WO2002046191A3 (en) 2003-03-13
HUP0600338A2 (en) 2006-08-28
AU3953002A (en) 2002-06-18
AU2002239530B2 (en) 2006-09-28
CA2436983A1 (en) 2002-06-13
PL366330A1 (en) 2005-01-24
TWI293300B (en) 2008-02-11
AU3061802A (en) 2002-06-18
HUP0600605A2 (en) 2006-11-28
AU2002232497B2 (en) 2006-11-02
EE200300272A (en) 2003-10-15
ZA200305275B (en) 2004-10-08
US20030212091A1 (en) 2003-11-13
EE200300268A (en) 2003-10-15
KR20040028690A (en) 2004-04-03
RU2351598C2 (en) 2009-04-10
EP1341792A2 (en) 2003-09-10
AU3951702A (en) 2002-06-18
WO2002046193A3 (en) 2003-02-27
DE60126645T2 (en) 2007-11-22
ZA200305274B (en) 2004-10-18
HRP20030467B1 (en) 2009-04-30
DK1341790T3 (en) 2007-06-04
MXPA03004973A (en) 2004-01-29
ZA200305272B (en) 2005-01-26
TWI222972B (en) 2004-11-01
JP2004523498A (en) 2004-08-05
CZ20031592A3 (en) 2004-01-14
RU2003116123A (en) 2004-11-20
NO20032473L (en) 2003-05-30
ATE319711T1 (en) 2006-03-15
SK287264B6 (en) 2010-04-07
US20040092545A1 (en) 2004-05-13
CZ20031563A3 (en) 2004-02-18
CZ20031591A3 (en) 2003-11-12
EE200300275A (en) 2003-10-15
CA2436980C (en) 2011-03-29
JP2010031040A (en) 2010-02-12
SK7152003A3 (en) 2003-09-11
TW584633B (en) 2004-04-21
EE200300274A (en) 2003-10-15
JP2004521092A (en) 2004-07-15
NZ526088A (en) 2004-12-24
PL365907A1 (en) 2005-01-10
EP1341791A2 (en) 2003-09-10
CN1511155A (en) 2004-07-07
AR035668A1 (en) 2004-06-23
NZ526089A (en) 2004-11-26
NO20032473D0 (en) 2003-05-30
CZ295848B6 (en) 2005-11-16
AR035664A1 (en) 2004-06-23
NZ526106A (en) 2004-11-26
BR0116470A (en) 2005-08-16
IL155950A0 (en) 2003-12-23
AU2002239517B2 (en) 2006-11-02
NZ526086A (en) 2005-11-25
AU2002239516B2 (en) 2006-11-09
PT1341790E (en) 2007-05-31
ZA200305271B (en) 2004-10-08
CA2436984A1 (en) 2002-06-13
EP1343784A2 (en) 2003-09-17
IL155904A0 (en) 2003-12-23
UA75622C2 (en) 2006-05-15
CY1105586T1 (en) 2010-07-28
KR20030070050A (en) 2003-08-27
HUP0700062A2 (en) 2007-05-02
CN1247575C (en) 2006-03-29
WO2002046188A2 (en) 2002-06-13
HRP20030464A2 (en) 2004-06-30
ZA200305270B (en) 2004-08-26
CN1253452C (en) 2006-04-26
WO2002046193A2 (en) 2002-06-13
HRP20030467A2 (en) 2004-04-30
DE60126645D1 (en) 2007-03-29
MXPA03004972A (en) 2004-01-29
SK7132003A3 (en) 2003-10-07
PL365883A1 (en) 2005-01-10
US20040106640A1 (en) 2004-06-03
HK1066005A1 (en) 2005-03-11
SK7122003A3 (en) 2003-11-04
ATE296301T1 (en) 2005-06-15
HRP20030462A2 (en) 2004-04-30
JP2004529078A (en) 2004-09-24
ES2260323T3 (en) 2006-11-01
RU2302418C2 (en) 2007-07-10
CZ20031561A3 (en) 2004-04-14
JP2004532810A (en) 2004-10-28
HRP20030461A2 (en) 2004-06-30
NO326159B1 (en) 2008-10-13
US20020193396A1 (en) 2002-12-19
ATE353895T1 (en) 2007-03-15
DK1341791T3 (en) 2005-09-19
US20030158192A1 (en) 2003-08-21
EP1343784B1 (en) 2006-03-08
WO2002046188A3 (en) 2003-03-13
CN1479739A (en) 2004-03-03
NO20032596L (en) 2003-06-06
PL207340B1 (en) 2010-12-31
JP2004515501A (en) 2004-05-27
EP1339715A2 (en) 2003-09-03
ZA200305273B (en) 2004-10-08
WO2002046189A3 (en) 2003-03-20
HRP20030463A2 (en) 2004-04-30
NO20032595L (en) 2003-06-06
MXPA03005011A (en) 2003-09-05
US7612083B2 (en) 2009-11-03
CN1479738A (en) 2004-03-03
CA2431151A1 (en) 2002-06-13
DE60117859T2 (en) 2006-11-23
NZ526087A (en) 2004-11-26
AR035669A1 (en) 2004-06-23
HRP20030466A2 (en) 2004-06-30
PL392462A1 (en) 2010-11-22
HUP0400710A2 (en) 2004-06-28
CN1537111A (en) 2004-10-13
AU2002232482B2 (en) 2006-10-19
AR035666A1 (en) 2004-06-23
WO2002046191A2 (en) 2002-06-13
HUP0400704A2 (en) 2004-06-28
PL366115A1 (en) 2005-01-24
US7049439B2 (en) 2006-05-23
IL155884A0 (en) 2003-12-23
DE60111076D1 (en) 2005-06-30
WO2002046190A2 (en) 2002-06-13
MXPA03004975A (en) 2003-09-05
SK6842003A3 (en) 2003-12-02
KR20040023576A (en) 2004-03-18
ES2281456T3 (en) 2007-10-01
KR20040047733A (en) 2004-06-05
CA2430844A1 (en) 2002-06-13
NO20032595D0 (en) 2003-06-06
NO20032596D0 (en) 2003-06-06
KR20040028691A (en) 2004-04-03
RU2003116063A (en) 2004-12-10
SK7112003A3 (en) 2003-12-02
CN1894244A (en) 2007-01-10
JP2004515500A (en) 2004-05-27
AU3248202A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO2002046192A3 (en) Thioether substituted imidazoquinolines
MXPA04005362A (en) Thioether substituted imidazoquinolines.
HK1086762A1 (en) Sulfonamide substituted imidazoquinolines
HK1044488A1 (en) Amide substituted imidazoquinolines
WO2005003065A3 (en) Sulfonamide substituted imidazoquinolines
WO2002046194A3 (en) Substituted imidazopyridines
IL146572A0 (en) Urea substituted imidazoquinolines
WO2003050119A3 (en) Urea substituted imidazopyridines
WO2004028539A3 (en) 1h-imidazo dimers
ZA200105452B (en) Compositions for the treatment of malaria.
SG122745A1 (en) Compositions for the treatment of malaria

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 155904

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526087

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2436846

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/004975

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2003-1560

Country of ref document: CZ

Ref document number: 1020037007534

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20030467A

Country of ref document: HR

Ref document number: 7102003

Country of ref document: SK

Ref document number: 2002547929

Country of ref document: JP

Ref document number: 01820161X

Country of ref document: CN

Ref document number: 2002239530

Country of ref document: AU

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 2003/05274

Country of ref document: ZA

Ref document number: 2001987297

Country of ref document: EP

Ref document number: 200305274

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020037007534

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500496

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2001987297

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1560

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 526087

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526087

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001987297

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2003-1560

Country of ref document: CZ